IL-11 muteins
US8540977B2 · kind B2 · utility
18Cited by
2References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jul 25, 2011 |
| Grant date | Sep 24, 2013 |
| Priority date | — |
| Expiry date | Jul 25, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.